Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study - Passamonti, F; Griesshammer, M; Palandri, F (Lancet Oncol, 2017)